Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-0633 placebo-controlled dose-ranging study in adults with chronic asthma
2008-005061-57Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Aug 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of MK-633 in asthma (4 arms), sponsored by Merck & Co. Primary endpoints: Primary efficacy endpoint and Dose-response objective. Started Aug 2008; status: terminated.
02
Drugs
MK-633
03
Conditions
asthma
Beyond the preview
Go deeper on 2008-005061-57.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005061-57.